Aktis Oncology, Inc. 8K

Aktis Oncology filed an 8-K to announce second quarter 2026 financial results and provide updates on its clinical programs, manufacturing build-out, and liquidity outlook.

On August 13, 2026, Aktis Oncology, Inc. reported its financial results for the quarter ended June 30, 2026 and provided business updates, highlighting ongoing enrollment in a Phase 1b trial for AKY-1189 in Nectin-4 expressing tumors, initiation and regulatory clearance for multiple Phase 1b trials of AKY-2519 in metastatic castration-resistant prostate cancer and other B7-H3 expressing solid tumors, progress toward bringing an in-house GMP manufacturing facility online in the second half of 2026, and a strong cash position of $517.3 million largely driven by proceeds from its January 2026 IPO, which is expected to fund operations into 2029 despite increased R&D and G&A expenses leading to a quarterly net loss of $24.1 million.

Filing Facts

CIK

2035832

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-349133

Alert Tier

5